Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 19, 2015

View Archived Issues

Reprogramming of delta and alpha cells associated with beta-cell independent insulin production

Amarantus BioScience reports data from LymPro Test

Garvan Institute spins off Solvanix

Milestone in Novogen's regenerative medicine program

Acorda Therapeutics provides overview on ongoing projects

Safety and dosing data presented for a novel gastric cancer vaccine

Ultragenyx Pharmaceuticals reviews pipeline

Alkermes presents overview of development pipeline at J.P. Morgan conference

Roche acquires Trophos to expand portfolio in neuromuscular disease

Alios BioPharma discloses new nuclosides for infections

LG Life Sciences patents novel FFA4 receptor antagonists

Genentech patent reports new EGFR T790M mutant inhibitors

New FPR2/ALX agonists designed by Actelion Pharmaceuticals

Scientists at Merck & Co. disclose novel NS5B inhibitors for HCV

Otezla receives approval in the E.U. for the treatment of psoriasis and psoriatic arthritis

Johnson & Johnson confirms formation of Ebola vaccine development consortia

NBI-77860 awarded U.S. orphan drug designation for congenital adrenal hyperplasia

Sanofi launches Allegra Dry Syrup 5% in Japan for allergic diseases

Antibe Therapeutics halts phase I ATB-345 trial due to safety concerns

Vect-Horus and Sanofi sign agreement for delivery of neurodegenerative disease therapy to brain

European Commission approves Ofev for idiopathic pulmonary fibrosis

Evotec and C4X Discovery collaborate to discover OX1 receptor inhibitors for addiction

Solasia and Meiji Seika sign Japanese license agreement for darinaparsin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...